3 results
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7502175 as a single…
Primary objective of the study:* To compare overall survival (OS) in the General Population patients treated with BBI-608 plus biweekly FOLFIRI (Arm 1) versus biweekly FOLFIRI (Arm 2)* To compare OS in the pSTAT3-positive (pSTAT3(+)) Subpopulation…
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7502175 as a single…